These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
643 related articles for article (PubMed ID: 33685606)
1. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. Pepper AN; Hanania NA; Humbert M; Casale TB J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1081-1088. PubMed ID: 33685606 [TBL] [Abstract][Full Text] [Related]
2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database. Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062 [TBL] [Abstract][Full Text] [Related]
3. Biologics in the treatment of asthma in children and adolescents. Bacharier LB; Jackson DJ J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649 [TBL] [Abstract][Full Text] [Related]
4. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma. Chan R; RuiWen Kuo C; Lipworth B J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880 [TBL] [Abstract][Full Text] [Related]
5. Choice of biologics in asthma endotypes. Wangberg H; Woessner K Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486 [TBL] [Abstract][Full Text] [Related]
6. The Current State of Biologic Therapies for Treatment of Refractory Asthma. Mavissakalian M; Brady S Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960 [TBL] [Abstract][Full Text] [Related]
8. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma. Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394 [TBL] [Abstract][Full Text] [Related]
9. Biological treatments for severe asthma: where do we stand? Busse WW Curr Opin Allergy Clin Immunol; 2018 Dec; 18(6):509-518. PubMed ID: 30299397 [TBL] [Abstract][Full Text] [Related]
10. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis. Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294 [TBL] [Abstract][Full Text] [Related]
12. [THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES]. Ito A; Miyoshi S; Toyota H; Suzuki Y; Uehara Y; Hattori S; Takeshita Y; Sakasegawa H; Kuramochi M; Kobayashi K; Sugimoto N; Nagase H Arerugi; 2022; 71(3):210-220. PubMed ID: 35569943 [TBL] [Abstract][Full Text] [Related]
13. New perspectives of childhood asthma treatment with biologics. Just J; Deschildre A; Lejeune S; Amat F Pediatr Allergy Immunol; 2019 Mar; 30(2):159-171. PubMed ID: 30444939 [TBL] [Abstract][Full Text] [Related]
14. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578 [TBL] [Abstract][Full Text] [Related]
15. Biological treatments for severe asthma: A major advance in asthma care. Busse WW Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118 [TBL] [Abstract][Full Text] [Related]
16. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals. Akenroye AT; Heyward J; Keet C; Alexander GC J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592 [TBL] [Abstract][Full Text] [Related]
17. Role of Biologics in Asthma. McGregor MC; Krings JG; Nair P; Castro M Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902 [TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Jackson K; Bahna SL Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421 [No Abstract] [Full Text] [Related]
19. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866 [TBL] [Abstract][Full Text] [Related]